Modulation of hippocampal activity in schizophrenia with levetiracetam: a randomized, double-blind, cross-over, placebo-controlled trial

MJ Roeske, M McHugo, B Rogers… - …, 2024 - nature.com
Hippocampal hyperactivity is a novel pharmacological target in the treatment of
schizophrenia. We hypothesized that levetiracetam (LEV), a drug binding to the synaptic …

The relationship between SV2A levels, neural activity, and cognitive function in healthy humans: a [11C] UCB-J PET and fMRI study

E Shatalina, EC Onwordi, T Whitehurst… - Imaging …, 2024 - direct.mit.edu
Synaptic terminal density is thought to influence cognitive function and neural activity, yet its
role in cognition has not been explored in healthy humans. We examined these …

Transcriptional and Cellular Response of hiPSC-derived Microglia-Neural Progenitor Co-Cultures Exposed to IL-6

ACM Couch, A Brown, M Taylor, L Sichlinger… - bioRxiv, 2023 - biorxiv.org
Elevated interleukin (IL-) 6 levels during prenatal development have been linked to
increased risk for neurodevelopmental disorders (NDD) in the offspring, but the mechanism …

In Vivo Synaptic Density in Early Schizophrenia: Are There No Differences or Are They Too Small to Detect?

R Radhakrishnan - Biological Psychiatry, 2024 - biologicalpsychiatryjournal.com
Schizophrenia is a chronic psychiatric disorder with a prevalence of approximately 1%
worldwide and incurs a high annual cost of approximately $343 billion. It continues to be …

Dysconnection in schizophrenia: filling the dots from old to new evidence

J Sapienza, F Pacchioni… - … : official journal of the …, 2024 - pubmed.ncbi.nlm.nih.gov
Dysconnection in schizophrenia: Filling the dots from old to new evidence Dysconnection in
schizophrenia: Filling the dots from old to new evidence Clin Neurophysiol. 2024 Mar 21:S1388-2457(24)00083-X …